Skip to content

Comparative in vivo evaluation of 2 Ranolazine 500mg ER Tablet and Ranexa® 500 mg ER Tablet formulations.

Comparative bioequivalence study of Ranolazine 500 mg ER Tablet of Zist Arvand Pharmed. and Ranexa® of A. Menarini Pharma GmbH as reference in 24 healthy male under fasting condition

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180620040164N77
Enrollment
24
Registered
2025-01-10
Start date
2025-01-31
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina pectoris. Angina pectoris

Interventions

Sponsors

Zist Arvand Pharme Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Healthy subjects (male) between 18 – 45 years of age. Body Mass Index (BMI) within 15% of normal range according to the accepted normal values between 18 and 27 (inclusive), calculated as kg/m2. General laboratory tests of biochemistry, hematology, TSH, HIV, HBs and HCV are performed. Subjects with no significant diseases or abnormal findings during laboratory evaluations and clinical examination. Subjects with normal vital signs.

Exclusion criteria

Exclusion criteria: Subjects with known allergy to the products tested. volunteers with associated acute or chronic infections; blood pressure in standing position and after at least 5 minutes of rest, systole less than 90 or more than 140 mmHg and diastole less than 50 or more than 90 mmHg); heart rate less than 50 or more than 90 beats per minute; Abnormalities in ECG include: (PR > 210 msec, QRS complex > 120 msec, QTcF > 430 msec); Smoking more than 10 cigarettes per day and could not tolerate cigarette cessation during each clinical period; A history of difficulty with donating blood or donation of more than 500 ml blood within 7 days prior to the start of the study;

Design outcomes

Primary

MeasureTime frame
Peak Plasma Concentration (Cmax). Timepoint: 16 blood samples will be withdrawn pre-dose and at 1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 24 and 48 hours after intervention. Method of measurement: Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA).

Secondary

MeasureTime frame
AUC (Area Under the Concentration-Time Curve). Timepoint: 16 blood samples will be withdrawn pre-dose and at 1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 24 and 48 hours after intervention. Method of measurement: Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehzad Montaha sangari

Noor Research & Development Institute

info@tavaninstitute.ir+98 21 6600 4027

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026